Drug Profile


Alternative Names: Amekrin; Amsa P-D; Amsidine; Amsidyl; CI 880; m AMSA; NSC 141549; NSC 156303; NSC 249992; SN 11841

Latest Information Update: 26 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Auckland Cancer Society Research Centre
  • Class Aminoacridines; Antineoplastics; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Leukaemia

Most Recent Events

  • 18 Apr 2016 ProStrakan is now called Kyowa Kirin International
  • 21 Apr 2011 ProStrakan has been acquired by Kyowa Hakko Kirin
  • 31 Jan 2004 OTL Pharma has been acquired by, and merged into, Strakan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top